Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: Results from a randomized, double-blind trial

British Journal of Dermatology

Volumn 161, Issue 2, 2009, Pages 427-434

  Doss, N ^a   Reitamo, S ^b   Dubertret, L ^c   Fekete, G L ^d   Kamoun, M R ^e   Lahfa, M ^c   Ortonne, J P ^f  

^a MILITARY HOSPITAL OF TUNIS   (Tunisia)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c SAINT LOUIS HOSPITAL   (France)

^d Dermatology Clinic   (Romania)

^e CHARLES NICOLLE HOSPITAL   (Tunisia)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Atopic dermatitis; Chronic facial erythema; Clinical trial; Fluticasone propionate ointment; Tacrolimus ointment; Topical calcineurin inhibitors

Indexed keywords

ANDROSTANE DERIVATIVE; DERMATOLOGICAL AGENT; FLUTICASONE; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FEMALE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; OINTMENT; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; ANDROSTADIENES; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FACIAL DERMATOSES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OINTMENTS; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67650555098     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09143.x     Document Type: Article

References (29)

1. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980; 92 (Suppl.): S44-7.
2. Weisshaar E, Apfelbacher C, Jager G et al. Pruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients. Br J Dermatol 2006; 155: 957-64.
3. Fivenson D, Arnold RJ, Kaniecki DJ et al. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. J Manag Care Pharm 2002; 8: 333-42.
4. Dubertret L. Eczéma atopique de l'adulte [Atopic dermatitis in adults]. Rev Prat 2006; 56: 266-72.
5. Omoto M, Sugiura H, Uehara M. Histopathological features of recalcitrant erythema of the face in adult patients with atopic dermatitis. J Dermatol 1994; 21: 87-91.
6. Morris AD. Effects of long-term topical corticosteroids. Dermatol Pract 1998; 6: 5-8.
7. Anon. Topical steroid allergy and dependence. Prescrire Int 2005; 14: 21-2.
8. Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye 2006; 20: 407-16.
9. McGhee CN, Dean S, Nesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf 2002; 25: 33-55.
10. Reitamo S, Ortonne JP, Sand C et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0Æ1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005; 152: 1282-9.
11. Sugiura H, Uehara M, Hoshino N et al. Long-term efficacy of tacrolimus ointment for recalcitrant facial erythema resistant to topical corticosteroids in adult patients with atopic dermatitis. Arch Dermatol 2000; 136: 1062-3.
12. Rajka G, Langeland T. Grading the severity of atopic dermatitis. Acta Derm Venereol (Stockh) 1989; 144 (Suppl.): S13-14.
13. Hanifin JM, Thurston M, Omoto M et al. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. EASI evaluator group. Exp Dermatol 2001; 10: 11-18.
14. Stander S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview. Exp Dermatol 2002; 11: 12-24.
15. Thestrup-Pedersen K. Clinical aspects of atopic dermatitis. Clin Exp Dermatol 2000; 25: 535-43.
16. Leung DY. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000; 105: 860-76.
17. Hanifin JM, Ling MR, Langley R et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001; 44: S28-38.
18. Soter NA, Fleischer AB Jr, Webster GF et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 2001; 44: S39-46.
19. Reitamo S, Rustin M, Ruzicka T et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 547-55.
20. Koo JY, Fleischer AB Jr, Abramovits W et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. J Am Acad Dermatol 2005; 53: S195-205.
21. Hanifin JM, Paller AS, Eichenfield L et al. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol 2005; 53 (Suppl. 2): S186-94.
22. Kang S, Paller A, Soter N et al. Safe treatment of head ?neck AD with tacrolimus ointment. J Dermatolog Treat 2003; 14: 86-94.
23. GlaxoSmithKline. FLIXOVATE-0.05 pour cent crème. FLIXOVATE-0.05 pour cent pommade. Propionate de fluticasone [Flixovate-0.05% cream, Flixovate-0.05% ointment. Fluticasone propionate]. Marly-le-Roi Cedex: Laboratoire GlaxoSmithKline, 2003.
24. Astellas Pharma GmbH. Summaries of Product Characteristics. Protopic 0.03% Ointment and Protopic 0.1% Ointment. Munich, Germany: Astellas Pharma GmbH, 2006.
25. French Consensus Conference. Management of atopic dermatitis in children. Recommendations (short version). Eur J Dermatol 2005; 15: 215-23.
26. Murrell DF, Calvieri S, Ortonne JP et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol 2007; 157: 954-9.
27. EMEA. Press release: European Medicines Agency Recommends Cautious Use of Protopic ? Protopy and Elidel. London: European Medicines Agency Press Office, 2006.
28. Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007; 214: 289-95.
29. Arellano FM, Wentworth CE, Arana A et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007; 127: 808-16.